Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

BACKGROUND: Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial. Numerically, more myocardial infarctions occurred in patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemens, Andreas, Fraessdorf, Mandy, Friedman, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798206/
https://www.ncbi.nlm.nih.gov/pubmed/24143109
http://dx.doi.org/10.2147/VHRM.S49830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798206/
https://www.ncbi.nlm.nih.gov/pubmed/24143109
http://dx.doi.org/10.2147/VHRM.S49830

Ejemplares similares